← The Wire·Consumer·

Alkermes' narcolepsy drug advances with positive Phase 2 results

Alkermes said its narcolepsy drug produced positive results in a Phase 2 trial, adding a potentially important development-stage asset to its portfolio. With no trial metrics or regulatory details disclosed here, the setup is constructive for the pipeline but not yet sufficient for a high-conviction earnings reset.

STOCK PHOTO · STAR ZHANG

The story

Alkermes' narcolepsy drug delivered positive results in a Phase 2 trial reported August 24. The asset adds to the pipeline of ALKS, whose FY 2025 revenue was $1.5B, down 5.2% YoY, with a 16.4% net margin and $1.43 diluted EPS. The concrete mechanism for the stock is therefore pipeline value: a successful program could broaden the company's future revenue base, while the current operating figures show that the market still has an established commercial business against which to measure the asset.

The next catalysts are fuller Phase 2 data, management's comments on durability and safety, and any decision to advance the program into late-stage testing. Key unknowns remain regarding how differentiated the drug is, how large the addressable opportunity could be, and how much development and regulatory work remains.

Our read · Mon, Aug 24

Alkermes (ALKS) said its narcolepsy drug produced positive results in a Phase 2 trial.

Why. The near-term value driver is optionality around a new narcolepsy program, layered onto ALKS’s $1.5B revenue base. That read is constructive, but the absence of efficacy, safety, and study-design details makes the likely magnitude of any repricing uncertain and argues for a modest target and tight risk definition.

Both cases

The case it holdsThe strongest bull case is that positive Phase 2 data validates a differentiated narcolepsy asset and gives ALKS a new future growth avenue beyond its $1.5B revenue base.
The case it breaksLimited bear case on the available facts, so the result may not yet establish a clinically meaningful or commercially differentiated product.

What could change this view: A weak or incomplete Phase 2 dataset, safety signal, or delay in advancing the program would remove the pipeline catalyst while the existing business is already showing 5.2% YoY revenue decline.

Alkermes stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Investing.comoriginalMon, Aug 24 · 6:36 PM ETAlkermes narcolepsy drug shows positive phase 2 trial results

Keep reading

Latest on the Wire

Nvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Investing.com as Alkermes narcolepsy drug shows positive phase 2 trial results, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →